Denna sida på svenska

Britta Wahren

Professor, senior

Visiting address : Smittskyddsinstitutet ; Nobels väg 21, 171 82 Solna, Sweden
Postal address : Department of Microbiology, Tumor and Cell Biology (MTC), C1, Francesca Chiodi group, , Sweden
Delivery address : Smittskyddsinstitutet ; Nobels väg 21, 171 82 Solna, Sweden

Publications

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees
Nilsson C, Godoy-ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, et al
AIDS research and human retroviruses 2014;30(3):299-311

Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression
Stenler S, Wiklander Op, Badal-tejedor M, Turunen J, Nordin Jz, Hallengärd D, et al
Molecular therapy. Nucleic acids 2014;2():e140-

Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa
Kilpeläinen A, Axelsson Robertson R, Leitner T, Sandström E, Maeurer M, Wahren B
AIDS research and human retroviruses 2014;30(11):1065-71

A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity
Hallengärd D, Wahren B, Bråve A
Viral immunology 2013;26(2):163-6

Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization
Isaguliants M, Smirnova O, Ivanov Av, Kilpelainen A, Kuzmenko Y, Petkov S, et al
Human vaccines & immunotherapeutics 2013;9(10):2111-9

Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness
Nowroozalizadeh S, Gudmundsdotter L, Hejdeman B, Andersson L, Esbjörnsson J, Medstrand P, et al
Human vaccines & immunotherapeutics 2013;9(10):2103-10

Therapeutic DNA Vaccination of Vertically HIV-Infected Children: Report of the First Pediatric Randomised Trial (PEDVAC)
Palma P, Romiti Ml, Montesano C, Santilli V, Mora N, Aquilani A, et al
PLOS ONE 2013;8(11):e79957-

A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines
Hallengärd D, Bråve A, Isaguliants M, Blomberg P, Enger J, Stout R, et al
Genetic vaccines and therapy 2012;10(1):5-

A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro
Chang Ch, Hinkula J, Loo M, Falkeborn T, Li Rx, Cardillo Tm, et al
PLOS ONE 2012;7(7):e41235-

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses
Hallengärd D, Applequist Se, Nyström S, Maltais Ak, Marovich M, Moss B, et al
Viral immunology 2012;25(5):423-32

Immunogenicity of HIV Virus-Like Particles in Rhesus Macaques by Intranasal Administration
Buonaguro L, Tagliamonte M, Visciano Ml, Andersen H, Lewis M, Pal R, et al
CLINICAL AND VACCINE IMMUNOLOGY 2012;19(6):970-3

Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein
Staff C, Magnusson Cg, Hojjat-farsangi M, Mosolits S, Liljefors M, Frödin Je, et al
Journal of clinical immunology 2012;32(4):855-65

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011
Ruffin N, Borggren M, Euler Z, Fiorino F, Grupping K, Hallengärd D, et al
Journal of translational medicine 2012;10():144-

Accumulation and activation of natural killer cells in local intraperitoneal HIV-1/MuLV infection results in early control of virus infected cells
Johansson Se, Brauner H, Hinkula J, Wahren B, Berg L, Johansson Mh
CELLULAR IMMUNOLOGY 2011;272(1):71-8

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial
Gudmundsdotter L, Wahren B, Haller Bk, Boberg A, Edback U, Bernasconi D, et al
VACCINE 2011;29(33):5558-66

A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients
Staff C, Mozaffari F, Haller Bk, Wahren B, Liljefors M
VACCINE 2011;29(39):6817-22

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
Hivis Study Grp, Bakari M, Aboud S, Nilsson C, Francis J, Buma D, et al
VACCINE 2011;29(46):8417-28

Comparison of Plasmid Vaccine Immunization Schedules Using Intradermal In Vivo Electroporation
Hallengard D, Haller Bk, Maltais Ak, Gelius E, Nihlmark K, Wahren B, et al
CLINICAL AND VACCINE IMMUNOLOGY 2011;18(9):1577-81

Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity
Hallengard D, Haller Bk, Petersson S, Boberg A, Maltais Ak, Isaguliants M, et al
VACCINE 2011;29(4):839-48

NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients
Johansson Se, Rollman E, Chung Aw, Center Rj, Hejdeman B, Stratov I, et al
VIRAL IMMUNOLOGY 2011;24(5):359-68

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010
Brinckmann S, Da Costa K, Van Gils Mj, Hallengard D, Klein K, Madeira L, et al
JOURNAL OF TRANSLATIONAL MEDICINE 2011;:40-

Safety and Efficacy of HIV Hyperimmune Globulin for Prevention of Mother-to-Child HIV Transmission in HIV-1-Infected Pregnant Women and Their Infants in Kampala, Uganda (HIVIGLOB/NVP STUDY)
Onyango-makumbi C, Omer Sb, Mubiru M, Moulton Lh, Nakabiito C, Musoke P, et al
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2011;58(4):399-407

The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children
Palma P, Romiti Ml, Pira Gl, Montesano C, Mora N, Aquilani A, et al
VACCINE 2011;29(39):6810-6

Biodistribution persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation
Brave A, Gudmundsdotter L, Sandstrom E, Haller Bk, Hallengard D, Maltais Ak, et al
VACCINE 2010;28(51):8203-9

Broad and strong immune responses in a trial of a heterologous DNA prime MVA boost HIV vaccine among healthy Tanzanian volunteers
Aboud S, Bakari M, Francis J, Buma D, Moshiro C, Aris Ea, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2010;26(10):A10-A10

Broad cellular and humoral immune responses after a second HIV-MVA vaccination in HIV-DNA primed HIV-MVA-boosted Swedish vaccinees
Nilsson C, Godoy-ramirez K, Brave A, Currier J, Marovich M, Polonis V, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2010;26(10):A91-A91

Comparison of three lymphoproliferation assays to monitor HIV-specific T-cell responses in vaccinees immunized with HIV-1 DNA vaccine and HIV-1 MVA
Godoy-ramirez K, Jernberg L, Karlen K, Edback U, Marovich M, Wahren B, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2010;26(10):A111-A111

Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes
Brave A, Johansson U, Hallengard D, Heidari S, Gullberg H, Wahren B, et al
VACCINE 2010;28(9):2080-7

NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients
Johansson Se, Hejdeman B, Hinkula J, Johansson Mh, Romagne F, Wahren B, et al
CLINICAL IMMUNOLOGY 2010;134(2):158-68

Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization
Starodubova E, Boberg A, Ivanov A, Latyshev O, Petrakova N, Kuzmenko Y, et al
VACCINE 2010;28(8):1975-86

Priming with plasmid DNA by electroporation and boosting with recombinant vaccinia virus Ankara induces polyfunctional immune responses in mice
Hallengard D, Applequist S, Nystrom S, Maltais A, Marovich M, Moss B, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2010;26(10):A92-A92

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference
Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, et al
JOURNAL OF TRANSLATIONAL MEDICINE 2010;:72-

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference (vol 8, pg 82, 2010)
Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, et al
JOURNAL OF TRANSLATIONAL MEDICINE 2010;:-

Strong HIV-Specific CD4(+) and CD8(+) T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes
Aboud S, Nilsson C, Karlen K, Marovich M, Wahren B, Sandstrom E, et al
CLINICAL AND VACCINE IMMUNOLOGY 2010;17(7):1124-31

Vaccine-induced seropositivity (VISP) following immunization of healthy individuals with HIV DNA and recombinant modified vaccinia virus Ankara
Brave A, Nilsson C, Biberfeld G, Earl P, Gudmundsdotter L, Hejdeman B, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2010;26(10):A11-A11

Acute-phase CD4(+) T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian-human immunodeficiency virus strain 89.6p-infected macaques
Koopman G, Mortier D, Hofman S, Koutsoukos M, Bogers Wmjm, Wahren B, et al
JOURNAL OF GENERAL VIROLOGY 2009;:915-26

A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al
RETROVIROLOGY 2009;:-

Determining the optimal protocol for plasmid DNA vaccine delivery by intradermal in vivo electroporation
Hallengard D, Brave A, Roos A, Gelius E, Nihlmark K, Wahren B
RETROVIROLOGY 2009;:-

Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen
Brave A, Hallengard D, Gudmundsdotter L, Stout R, Walters R, Wahren B, et al
VACCINE 2009;27(28):3692-6

Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells
Hinkula J, Walther-jallow L, Lauren A, Makitalo B, Oberg M, Wahren B, et al
VACCINE 2009;27(46):6424-31

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, et al
VACCINE 2009;27(33):4468-74

Skin Electroporation: Effects on Transgene Expression, DNA Persistence and Local Tissue Environment
Roos Ak, Eriksson F, Timmons Ja, Gerhardt J, Nyman U, Gudmundsdotter L, et al
PLOS ONE 2009;4(9):e7226-

Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA)
Nilsson C, Aboud S, Karlen K, Marovich M, Wahren B, Sandstrom E, et al
RETROVIROLOGY 2009;:-

Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Vaccine Boosted with Heterologous HIV-1 Recombinant Modified Vaccinia Virus Ankara
Hiv Immunogenicity Study 01 02 Tea, Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, et al
JOURNAL OF INFECTIOUS DISEASES 2008;198(10):1482-90

Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles
Gudmundsdotter L, Bernasconi D, Hejdeman B, Sandstrom E, Alaeus A, Lidman K, et al
VACCINE 2008;26(40):5182-7

Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants
Palma P, Romiti Ml, Cancrini C, Pensieroso S, Montesano C, Bernardi S, et al
VACCINE 2008;26(40):5196-201

Detection of pancreatic cancer using antibody microarray-based serum protein profiling
Ingvarsson J, Wingren C, Carlsson A, Ellmark P, Wahren B, Engstrom G, et al
PROTEOMICS 2008;8(11):2211-9

Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin
Boberg A, Gaunitz S, Brave A, Wahren B, Carlin N
VACCINE 2008;26(40):5079-82

HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response
Starodubova Es, Boberg A, Litvina M, Morozov A, Petrakova Nv, Timofeev A, et al
VACCINE 2008;26(40):5170-6

Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination
Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, et al
JOURNAL OF GENERAL VIROLOGY 2008;:540-53

Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses
Brave A, Hallengard D, Schroder U, Blomberg P, Wahren B, Hinkula J
VACCINE 2008;26(40):5075-8

Long-term increase of CD4(+) central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization
Gudmundsdotter L, Bostrom Ac, Burton C, Rosignoli G, Sandstrom E, Hejdeman B, et al
VACCINE 2008;26(40):5107-10

Murine models for HIV vaccination and challenge
Boberg A, Brave A, Johansson S, Wahren B, Hinkula J, Rollman E
EXPERT REVIEW OF VACCINES 2008;7(1):117-30

Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice
Hinkula J, Hagbom M, Wahren B, Schroder U
VACCINE 2008;26(40):5101-6

A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice
Brave A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, et al
MOLECULAR THERAPY 2007;15(9):1724-33

Candidate HIV-1 gpl40 Delta V2, gag and tat vaccines protect against experimental HIV-1/MuLV challenge
Brave A, Hinkula J, Cafaro A, Eriksson Le, Srivastava Ik, Magnani M, et al
VACCINE 2007;25(39-40):6882-90

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
Buonaguro L, Devito C, Tornesello Ml, Schroder U, Wahren B, Hinkula J, et al
VACCINE 2007;25(32):5968-77

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model
Rollman E, Mathy N, Brave A, Boberg A, Kjerrstrom A, Van Wely C, et al
VACCINE 2007;25(11):2145-54

Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology
Bråve A, Gudmundsdotter L, Gasteiger G, Hallermalm K, Kastenmuller W, Rollman E, et al
Infectious agents and cancer 2007;2():14-

Immunization with HIV protease peptides linked to syngeneic erythrocytes
Boberg A, Dominici S, Brave A, Hallermalm K, Hinkula J, Magnani M, et al
Infectious agents and cancer 2007;2():9-

Intracellular targeting of CEA results in th1-type antibody responses following intradermal genetic vaccination by a needle-free jet injection device
Johansson S, Ek M, Wahren B, Stout R, Liu Ma, Hallermalm K
THESCIENTIFICWORLDJOURNAL 2007;:987-99

Potent cellular and humoral immunity against HIV-1 elicited preclinically and clinically by a DNA-prime/MVA-boost vaccine regimen
Wahren B, Brave A, Ljungberg K, Gudmundsdotter L, Boberg A, Cox J, et al
HUMAN GENE THERAPY 2007;18(10):962-962

Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer
Hallermalm K, Johansson S, Brave A, Ek M, Engstrom G, Boberg A, et al
SCANDINAVIAN JOURNAL OF IMMUNOLOGY 2007;66(1):43-51

Vaccine delivery methods using viral vectors
Brave A, Ljungberg K, Wahren B, Liu Ma
MOLECULAR PHARMACEUTICS 2007;4(1):18-32

A nonsense mutation (428G -> A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection
Kindberg E, Hejdeman B, Bratt G, Wahren B, Lindblom B, Hinkula J, et al
AIDS 2006;20(5):685-9

A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations
Hinkula J, Devito C, Zuber B, Benthin R, Ferreira D, Wahren B, et al
VACCINE 2006;24(21):4494-7

Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience
Ferrantelli F, Butto S, Cafaro A, Wahren B, Ensoli B
SPRINGER SEMINARS IN IMMUNOPATHOLOGY 2006;28(3):289-301

DNA vaccines for HIV/AIDS
Ulmer Jb, Wahren B, Liu Ma
CURRENT OPINION IN HIV AND AIDS 2006;1(4):309-13

DNA vaccines: Recent developments and future possibilities
Liu Ma, Wahren B, Hedestam Gbk
HUMAN GENE THERAPY 2006;17(11):1051-61

Elevated levels of serum perforin in chronic HIV-1 and acute SIV/SHIV infection
Klingstrom J, Gudmundsdotter L, Zuber B, Hinkula J, Morner A, Wahren B, et al
AIDS 2006;20(1):125-7

Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody
Johansson S, Goldenberg Dm, Griffiths Gl, Wahren B, Hinkula J
AIDS 2006;20(15):1911-5

Gene-based vaccines: recent technical and clinical advances
Ulmer Jb, Wahren B, Liu Ma
TRENDS IN MOLECULAR MEDICINE 2006;12(5):216-22

HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1
Starodubova E, Boberg A, Kashuba Ev, Wahren B, Karpov V, Isaguliants M
VACCINE 2006;24(21):4541-7

Human immunodeficiency virus-type 1 specific cellular immunity in chronic infected patients on prolonged highly active antiretroviral treatment and on structured treatment interruption
Matsuda R, Bostrom Ac, Fredriksson M, Fredriksson El, Bratt G, Hejdeman B, et al
MICROBIOLOGY AND IMMUNOLOGY 2006;50(8):629-35

Immunological cross-reactivity against a drug mutated HIV-1 protease epitope after DNA multi-CTL epitope construct immunization
Boberg A, Sjostrand D, Rollman E, Hinkula J, Zuber B, Wahren B
VACCINE 2006;24(21):4527-30

Minimal change in HSV-2 seroreactivity: A cross-sectional Swedish population study
Jonsson Mk, Levi M, Ruden U, Wahren B
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2006;38(5):357-65

Molecular analysis and phylogenetic characterization of HIV in Iran
Sarrami-forooshani R, Das Sr, Sabahi F, Adeli A, Esmaeili R, Wahren B, et al
JOURNAL OF MEDICAL VIROLOGY 2006;78(7):853-63

Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine
Brave A, Ljungberg K, Boberg A, Rollman E, Engstrom G, Hinkula J, et al
VACCINE 2006;24(21):4524-6

Responses of mice immunized with a DNA vaccine encoding carcinoembryonic antigen (CEA)
Johansson S, Engstrom G, Winberg G, Hinkula J, Wahren B
VACCINE 2006;24(21):4572-5

Therapeutic immunization for HIV
Gudmundsdotter L, Sjodin A, Bostrom Ac, Hejdeman B, Theve-palm R, Alaeus A, et al
SPRINGER SEMINARS IN IMMUNOPATHOLOGY 2006;28(3):221-30

Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH
Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, et al
VIRAL IMMUNOLOGY 2005;18(4):678-88

DNA vaccines: Progress and challenges
Donnelly Jj, Wahren B, Liu Ma
JOURNAL OF IMMUNOLOGY 2005;175(2):633-9

Genetic diversity and phylogenetic analysis of human immunodeficiency virus type 1 circulating in Iran
Sarrami R, Mahboudi F, Adeli A, Jamal S, Wahren B
FEBS JOURNAL 2005;:128-128

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Yh, et al
NUCLEIC ACIDS RESEARCH 2005;33(1):439-47

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery
Brave A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, et al
MOLECULAR THERAPY 2005;12(6):1197-205

The rationale behind a vaccine based on multiple HIV antigens
Rollman E, Brave A, Boberg A, Gudmundsdotter L, Engstrom G, Isaguliants A, et al
MICROBES AND INFECTION 2005;7(14):1414-23

Autologous cytotoxicity of natural killer cells derived from HIV-infected patients
Hultstrom Al, Bratt G, Cosma A, Erfle V, Wahren B, Carbone E
IMMUNOLOGY LETTERS 2004;91(2-3):155-8

Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site
Rowcliffe E, Bolmstedt A, Biller M, Wahren B, Olofsson S, Hinkula J
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2004;36(5):360-4

DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy
Hejdeman B, Bostrom Ac, Matsuda R, Calarota S, Lenkei R, Fredriksson El, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2004;20(8):860-70

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen
Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K, Morner A, et al
JOURNAL OF GENERAL VIROLOGY 2004;:2407-19

Gene immunization may induce secondary antibodies reacting with DNA
Isaguliants Mg, Iakimtchouk K, Petrakova Nv, Yermalovich Ma, Zuber Ak, Kashuba Vi, et al
VACCINE 2004;22(11-12):1576-85

Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo
Hinkula J, Rollman E, Lundholm P, Benthin R, Okuda K, Wahren B
CELLS TISSUES ORGANS 2004;177(3):169-84

HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses
Rollman E, Arnheim L, Collier B, Oberg D, Hall H, Klingstrom J, et al
VIROLOGY 2004;322(1):182-9

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity
Devito C, Zuber B, Schroder U, Benthin R, Okuda K, Broliden K, et al
JOURNAL OF IMMUNOLOGY 2004;173(11):7078-89

Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication
Elmen J, Zhang Hy, Zuber B, Ljungberg K, Wahren B, Wahlestedt C, et al
FEBS LETTERS 2004;578(3):285-90

Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV)
Bostrom Ac, Hejdeman B, Matsuda R, Fredriksson M, Fredriksson El, Bratt G, et al
VACCINE 2004;22(13-14):1683-91

Minor nef gene alterations after human HIV-DNA immunisation
Aleman S, Leitner T, Liu Ma, Wahren B
AIDS 2004;18(5):817-9

Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies
Rollman E, Hinkula J, Arteaga J, Zuber B, Kjerrstrom A, Liu M, et al
GENE THERAPY 2004;11(14):1146-54

Mutations conferring drug resistance affect eukaryotic expression of HIV type 1 reverse transcriptase
Isaguliants Mg, Belikov Sv, Starodubova Es, Gizatullin Rz, Rollman E, Zuber B, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2004;20(2):191-201

Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus
Cosma A, Buhler S, Nagaraj R, Staib C, Hammarin Al, Wahren B, et al
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 2004;11(2):406-10

Primary murine cells as a model for HIV-1 infection
Lund Lh, Ljungberg K, Wahren B, Hinkula J
AIDS 2004;18(7):1067-9

Sexually transmitted herpes simplex viruses
Jonsson Mk, Wahren B
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2004;36(2):93-101

Support for the RV144 HIV vaccine trial
Belshe R, Franchini G, Girard Mp, Gotch F, Kaleebu P, Marthas Ml, et al
SCIENCE 2004;305(5681):177-80

Therapeutic vaccination against HIV
Wahren B, Liu M
Expert review of vaccines 2004;3(4 Suppl):S179-88

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA
Zuber Ak, Brave A, Engstrom G, Zuber B, Ljungberg K, Fredriksson M, et al
VACCINE 2004;22(13-14):1791-8

A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo
Lund Lh, Wahren B, Garcia-blanco Ma
JOURNAL OF GENERAL VIROLOGY 2003;:603-6

A multiplex real-time PCR for quantification of HIV-1 DNA and the human albumin gene in CD4(+) cells
Eriksson Le, Leitner T, Wahren B, Bostrom Ac, Falk Ki
APMIS 2003;111(6):625-33

Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up
Hejdeman B, Leandersson Ac, Fredriksson El, Sandström E, Wahren B, Bratt G
HIV medicine 2003;4(2):101-10

Choosing CCR5 or Rev siRNA in HIV-1
Arteaga Hj, Hinkula J, Van Dijk-hard I, Dilber Ms, Wahren B, Christensson B, et al
NATURE BIOTECHNOLOGY 2003;21(3):230-1

Clinical trials of genetic vaccination against HIV
Wahren B
JOURNAL OF GENE MEDICINE 2003;5(3):S30-S30

Efficient inhibition of HIV-1 infection by plasmid-encoded siRNA against CCR5 and rev transcripts
Arteaga Jh, Himkula J, Van Dijk-hard If, Dilber Sm, Wahren B, Christensson B, et al
MOLECULAR THERAPY 2003;7(5):S303-S303

Genetic immunization is augmented by murine polyomavirus VP1 pseudocapsids
Rollman E, Ramqvist T, Zuber B, Tegerstedt K, Zuber Ak, Klingstrom J, et al
VACCINE 2003;21(19-20):2263-7

HIV type 1 DNA development during long-term supervised therapy interruption
Eriksson Le, Falk Ki, Bratt Ga, Leandersson Ac, Wahren B, Leitner T
AIDS RESEARCH AND HUMAN RETROVIRUSES 2003;19(4):259-65

Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase
Mousavi-jazi M, Schloss L, Wahren B, Brytting M
JOURNAL OF CLINICAL VIROLOGY 2003;26(3):301-6

Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system
Lund Lh, Andersson K, Zuber B, Karlsson A, Engstrom G, Hinkula J, et al
CANCER GENE THERAPY 2003;10(5):365-76

Topical administration of imiquimod enhances cellular immune responses induced by HIV-1 Gene-Gun DNA vaccination
Zuber Ak, Zuber B, Petrovic J, Ljungberg K, Fredriksson M, Benthin R, et al
JOURNAL OF GENE MEDICINE 2003;5(3):S31-S31

A novel potent strategy for induction of immunity to HIV-1 reverse tramscriptase in primates
Zuber B, Makitalo B, Zuber Ak, Wahren B
AIDS 2002;16(13):1839-40

DNA mucosal HIV vaccine in humans
Lundholm P, Leandersson Ac, Christensson B, Bratt G, Sandstrom E, Wahren B
VIRUS RESEARCH 2002;82(1-2):141-5

DNA vaccination of ferrets with chimeric influenza - A virus hemagglutinin (H3) genes
Ljungberg K, Kolmskog C, Wahren B, Van Amerongen G, Baars M, Osterhaus A, et al
VACCINE 2002;20(16):2045-52

Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes
Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B
VIROLOGY 2002;302(1):44-57

HIV immunology better understood and vaccination attempts started
Wahren B, Landay A
AIDS 2002;:S85-8

HIV subtypes and recombination strains-strategies for induction of immune responses in man
Wahren B, Ljungberg K, Rollman E, Levi M, Zuber B, Zuber Ak, et al
VACCINE 2002;20(15):1988-93

Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells
Spetz Al, Sorensen As, Walther-jallow L, Wahren B, Andersson J, Holmgren L, et al
JOURNAL OF IMMUNOLOGY 2002;169(10):5771-9

Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda
Guay La, Musoke P, Hom Dl, Nakabiito C, Bagenda D, Fletcher Cv, et al
AIDS 2002;16(10):1391-400

Smallpox-eradicated, but a growing terror threat
Tegnell A, Wahren B, Elgh F
CLINICAL MICROBIOLOGY AND INFECTION 2002;8(8):504-9

Subtypes A, C, G, and recombinant HIV type 1 are circulating in Bangladesh
Ljungberg K, Hassan Ms, Islam Mn, Siddiqui Ma, Aziz Mm, Wahren B, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2002;18(9):667-70

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
Zou Lp, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B, et al
NEUROPHARMACOLOGY 2002;42(5):731-9

An in vivo model for HIV resistance development
Zuber B, Bottiger D, Benthin R, Ten Haaft P, Heeney J, Wahren B, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2001;17(7):631-5

Cellular HIV-1 immune responses in natural infection and after genetic immunization
Calarota Sa, Wahren B
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 2001;33(2):83-96

Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection
Hejdeman B, Lenkei R, Leandersson Ac, Hultstrom Al, Wahren B, Sandstrom E, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2001;17(4):277-86

DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector
Tahtinen M, Strengell M, Collings A, Pitkanen J, Kjerrstrom A, Hakkarainen K, et al
VACCINE 2001;19(15-16):2039-47

Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals - Effects of elimination of the V3N306 glycan
Bolmstedt A, Hinkula J, Rowcliffe E, Biller M, Wahren B, Olofsson S
VACCINE 2001;20(3-4):397-405

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity
Calarota Sa, Kjerrstrom A, Islam Kb, Wahren B
HUMAN GENE THERAPY 2001;12(13):1623-37

HIV in Europe - a growing threat
Wahren B
JOURNAL OF CLINICAL VIROLOGY 2001;21(2):171-3

Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines
Kjerrstrom A, Hinkula J, Engstrom G, Ovod V, Krohn K, Benthin R, et al
VIROLOGY 2001;284(1):46-61

Measurement of vaccination-induced cell mediated immunity against HIV, hepatitis, influenza and bacterial infections
Kowalski Rj, Woodcock Jb, Leandersson Ac, Wahren B
FASEB JOURNAL 2001;15(5):A1188-A1188

Protection against influenza virus challenge by topical application of influenza DNA vaccine
Watabe S, Xin Kq, Ihata A, Liu Lj, Honsho A, Aoki I, et al
VACCINE 2001;19(31):4434-44

Rapid and wide-reaching delivery of HIV-1 env DNA vaccine by intranasal administration
Tadokoro K, Koizumi Y, Miyagi Y, Kojima Y, Kawamoto S, Hamajima K, et al
VIRAL IMMUNOLOGY 2001;14(2):159-67

Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity
Mousavi-jazi M, Schloss L, Drew Wl, Linde A, Miner Rc, Harmenberg J, et al
JOURNAL OF CLINICAL VIROLOGY 2001;23(1-2):1-15

A retro-inverso miniantibody with anti-HIV activity
Levi M, Hinkula J, Wahren B
AIDS RESEARCH AND HUMAN RETROVIRUSES 2000;16(1):59-65

Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase.
Mousavi-jazi M, Linde A, Wahren B, Brytting M
ANTIVIRAL RESEARCH 2000;46(1):A81-A81

Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1
Leandersson Ac, Gilljam G, Fredriksson M, Hinkula J, Alaeus A, Lidman K, et al
JOURNAL OF VIROLOGY 2000;74(10):4888-90

DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge
Isaguliants Mg, Petrakova N, Zuber B, Pokrovskaya K, Gizatullin R, Kostyuk Da, et al
INTERVIROLOGY 2000;43(4-6):288-93

Effective construction of DNA vaccines against variable influenza genes by homologous recombination
Ljungberg K, Wahren B, Almqvist J, Hinkula J, Linde A, Winberg G
VIROLOGY 2000;268(2):244-50

GFP production in the rabbit temporomandibular joint after DNA injection.
Fredriksson L, Alstergren P, Kopp S, Lundholm P, Wahren B
JOURNAL OF DENTAL RESEARCH 2000;:321-321

Growth phenotypes of cytomegalovirus isolates do not correlate with glycoprotein B, major immediate early genotypes or antiviral sensitivity
Mousavi-jazi M, Sundqvist Va, Linde A, Wahren B, Brytting M
JOURNAL OF MEDICAL VIROLOGY 2000;62(2):117-26

[HIV epidemics without mercy. Several generations of children and adolescents in many African countries will be eradicated]
Wahren B, Sandström E
Lakartidningen 2000;97(32-33):3482-3

Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts
Cerboni C, Mousavi-jazi M, Linde A, Soderstrom K, Brytting M, Wahren B, et al
JOURNAL OF IMMUNOLOGY 2000;164(9):4775-82

Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization
Sandberg Jk, Leandersson Ac, Devito C, Kohleisen B, Erfle V, Achour A, et al
VIROLOGY 2000;273(1):112-9

Human natural killer cells in asymptomatic human immunodeficiency virus-1 Infection
Hulstrom Al, Hejdeman B, Leandersson Ac, Bratt G, Carbone E, Wahren B
INTERVIROLOGY 2000;43(4-6):294-301

Immunogenic properties of reverse transcriptase of HIV type 1 assessed by DNA and protein immunization of rabbits
Isaguliants Mg, Gudima So, Ivanova Ov, Levi M, Hinkula J, Garaev Mm, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 2000;16(13):1269-80

Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge
Zuber B, Hinkula J, Vodros D, Lundholm P, Nilsson C, Morner A, et al
VIROLOGY 2000;278(2):400-11

In vivo-pulsed dendritic cells: a promising approach for immunotherapy of autoimmune diseases
Huang Ym, Xiao Bg, Xu Ly, Yang Js, Van Der Meide Ph, Levi M, et al
JOURNAL OF INVESTIGATIVE DERMATOLOGY 2000;114(1):231-231

Limitation of nitric oxide production: cells from lymph node and spleen exhibit distinct difference in nitric oxide production
Xu Ly, Yang Js, Huang Ym, Van Der Meide Ph, Levi M, Wahren B, et al
IMMUNOLOGY LETTERS 2000;71(3):177-84

Mapping of B-cell epitopes on human Parvovirus B19 non-structural and structural proteins
Tolfvenstam T, Lundqvist A, Levi M, Wahren B, Broliden K
VACCINE 2000;19(7-8):758-63

P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice
Zou Lp, Ljunggren Hg, Levi M, Nennesmo I, Wahren B, Mix E, et al
JOURNAL OF NEUROSCIENCE RESEARCH 2000;62(5):717-21

Parvovirus B19 infection: association with third-trimester intrauterine fetal death
Skjoldebrand-sparre K, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 2000;107(4):476-80

Parvovirus B19 infection: association with third-trimester intrauterine fetal death - Authors' reply
Broliden K, Petterson K, Papadogiannakis N, Wahren B, Skjoldebrand-sparre L, Nyman M
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 2000;107(10):1324-1324

Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats
Zou Lp, Deretzi G, Levi M, Wahren B, Quiding C, Van Der Meide P, et al
NEUROPHARMACOLOGY 2000;39(2):324-33

Seroprevalence of viral childhood infections in Eritrea
Tolfvenstam T, Enbom M, Ghebrekidan H, Ruden U, Linde A, Grandien M, et al
JOURNAL OF CLINICAL VIROLOGY 2000;16(1):49-54

Th1-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production
Asakura Y, Liu Lj, Shono N, Hinkula J, Kjerrstrom A, Aoki I, et al
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2000;119(1):130-9

The complexity of cytokine treatment in ongoing EAE induced with MBP peptide 68-86 in Lewis rats
Xu Ly, Ishikawa M, Huang Ym, Levi M, Van Der Meide Ph, Wahren B, et al
CLINICAL IMMUNOLOGY 2000;95(1):70-8

A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis
Hultcrantz R, Olsson R, Danielsson B, Jarnerot C, Loof L, Ryden Bo, et al
JOURNAL OF HEPATOLOGY 1999;30(4):669-73

All cases of intrauterine fetal death should be evaluated for parvovirus B19 viral deoxyribonucleic acid
Skjoldebrand-sparre L, Nyman M, Broliden K, Wahren B
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 1999;180(6):1595-6

Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats
Zou Lp, Ma Dh, Levi M, Wahren B, Wei L, Mix E, et al
JOURNAL OF NEUROIMMUNOLOGY 1999;94(1-2):109-21

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma
Mosolits S, Harmenberg U, Ruden U, Ohman L, Nilsson B, Wahren B, et al
CANCER IMMUNOLOGY IMMUNOTHERAPY 1999;47(6):315-20

Dendritic cell-derived nitric oxide is involved in IL-4-induced suppression of experimental allergic encephalomyelitis (EAE) in Lewis rats
Xu Ly, Huang Ym, Yang Js, Van Der Meide Ph, Levi M, Wahren B, et al
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 1999;118(1):115-21

DNA-plasmids of HIV-1 induce systemic and mucosal immune responses
Asakura Y, Lundholm P, Kjerrstrom A, Benthin R, Lucht E, Fukushima J, et al
BIOLOGICAL CHEMISTRY 1999;380(3):375-9

Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model
Andang M, Hinkula J, Hotchkiss G, Larsson S, Britton S, Wong-staal F, et al
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1999;96(22):12749-53

Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase
Isaguliants Mg, Pokrovskaya K, Kashuba Vi, Pokholok D, Hinkula J, Wahren B, et al
FEBS LETTERS 1999;447(2-3):232-6

Expression of HIV regulatory DNA vaccine constructs
Kjerrstrom A, Wahren B
BIOGENIC AMINES 1999;15(1):93-112

Human cytomegalovirus strain-dependent changes in natural killer cell recognition of infected fibroblasts.
Cerboni C, Mousavi-jazi M, Linde A, Wahren B, Karre K, Carbone E
JOURNAL OF LEUKOCYTE BIOLOGY 1999;:11-11

Immune correlates of protection from HIV and AIDS - more answers but yet more questions
Heeney Jl, Beverley P, Mcmichael A, Shearer G, Strominger J, Wahren B, et al
IMMUNOLOGY TODAY 1999;20(6):247-51

Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
Calarota Sa, Leandersson Ac, Bratt G, Hinkula J, Klinman Dm, Weinhold Kj, et al
JOURNAL OF IMMUNOLOGY 1999;163(4):2330-8

Immunisation with gp160 in HIV-1 infection - Reply
Sandstom Eg, Wahren B
LANCET 1999;354(9182):949-949

Immunogenetic properties of genes
Wahren B
ACTA ONCOLOGICA 1999;38(3):309-11

Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1
Gilljam G, Svensson A, Ekstrom A, Wahren B
AIDS RESEARCH AND HUMAN RETROVIRUSES 1999;15(10):899-907

Induction of experimental autoimmune neuritis in CD4(-)8(-) C57BL/6J mice
Zhu J, Nennesmo I, Deng Gm, Levi M, Wahren B, Diab A, et al
JOURNAL OF NEUROIMMUNOLOGY 1999;94(1-2):196-203

Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA
Lundholm P, Asakura Y, Hinkula J, Lucht E, Wahren B
VACCINE 1999;17(15-16):2036-42

Is there a focus of HTLV-II infections in the horn of Africa?
Andersson S, Tessema Hg, Wahren B
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 1999;21(4):353-4

Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment
Bratt G, Eriksson Le, Sandstrom E, Gilljam G, Hinkula J, Albert J, et al
INTERNATIONAL JOURNAL OF STD & AIDS 1999;10(8):514-21

Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination
Deretzi G, Zou Lp, Pelidou Sh, Nennesmo I, Levi M, Wahren B, et al
JOURNAL OF AUTOIMMUNITY 1999;12(2):81-9

Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea
Ghebrekidan H, Ruden U, Cox S, Wahren B, Grandien M
JOURNAL OF CLINICAL VIROLOGY 1999;12(1):53-64

[Promising experiments with DNA vaccine against HIV. A complete eradication of the virus is a formidable task]
Wahren B
Lakartidningen 1999;96(7):722-5

Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions
Jackson Nac, Levi M, Wahren B, Dimmock Nj
JOURNAL OF GENERAL VIROLOGY 1999;:225-36

Seroprevalence of human herpes virus 8 in different Eritrean population groups
Enbom M, Tolfvenstam T, Ghebrekidan H, Ruden U, Grandien M, Wahren B, et al
JOURNAL OF CLINICAL VIROLOGY 1999;14(3):167-72

Suppression of chronic experimental autoimmune neuritis by nasally administered recombinant rat interleukin-6
Deretzi G, Pelidou Sh, Zou Lp, Quiding C, Mix E, Levi M, et al
IMMUNOLOGY 1999;97(1):69-76

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial
Nordic Vac-04 Study Grp, Sandstrom E, Wahren B
LANCET 1999;353(9166):1735-42

The role of B-cells in experimental myasthenia gravis in mice
Wang Hb, Li H, He B, Bakheit M, Levi M, Wahren B, et al
BIOMEDICINE & PHARMACOTHERAPY 1999;53(5-6):227-33

The use of peptides from glycoproteins G-2 and D-1 for detecting herpes simplex virus type 2 and type-common antibodies
Levi M, Ruden U, Carlberg H, Wahren B
JOURNAL OF CLINICAL VIROLOGY 1999;12(3):243-52

[A review of the current research on prions. The evidence suggests the possibility of transmission of the mad cow disease to humans]
Grandien M, Wahren B
Lakartidningen 1998;95(48):5499-500

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson Ac, Sandstrom E, et al
LANCET 1998;351(9112):1320-5

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection
Loomis-price Ld, Cox Jh, Mascola Jr, Vancott Tc, Michael Nl, Fouts Tr, et al
JOURNAL OF INFECTIOUS DISEASES 1998;178(5):1306-16

Experimental autoimmune myasthenia gravis induction in B cell-deficient mice
Li Hl, Shi Fd, He B, Bakheit M, Wahren B, Berglof A, et al
INTERNATIONAL IMMUNOLOGY 1998;10(9):1359-65

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells
Drexler I, Heller K, Wahren B, Erfle V, Sutter G
JOURNAL OF GENERAL VIROLOGY 1998;:347-52

HIV cDNA plasmids as immunotherapy
Wahren B, Calarota S, Leanderson Ac, Kjerrstrom A, Hejdeman B, Hultstrom Al, et al
AIDS 1998;:S103-S103

Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
Putkonen P, Quesada-rolander M, Leandersson Ac, Schwartz S, Thorstensson R, Okuda K, et al
VIROLOGY 1998;250(2):293-301

Immunoglobulin G abnormalities in HIV-1 infected individuals with lymphoma
Lundholm P, Lucht E, Svedmyr E, Ruden U, Linde A, Wahren B
IMMUNOTECHNOLOGY 1998;4(1):29-36

Induction of specific T-cell responses in HIV infection
Leandersson Ac, Bratt G, Hinkula J, Gilljam G, Cochaux P, Samson M, et al
AIDS 1998;12(2):157-66

Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99
Liu Jq, Bai Xf, Shi Fd, Xiao Bg, Li Hl, Levi M, et al
INTERNATIONAL IMMUNOLOGY 1998;10(8):1139-48

Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines
Diab A, Michael L, Wahren B, Deng Gm, Bjork J, Hedlund G, et al
JOURNAL OF NEUROIMMUNOLOGY 1998;85(2):146-54

Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats
Zhu J, Diab A, Mustafa M, Levi M, Wahren B, Bjork J, et al
JOURNAL OF THE NEUROLOGICAL SCIENCES 1998;160(2):113-20

MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals
Bratt G, Leandersson Ac, Albert J, Sandstrom E, Wahren B
AIDS 1998;12(7):729-36

Pharmacological administration of granulocyte/macrophage-calony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
Samanci A, Yi Q, Fagerberg J, Strigard K, Smith G, Ruden U, et al
CANCER IMMUNOLOGY IMMUNOTHERAPY 1998;47(3):131-42

Prevalence of infection with HIV, hepatitis B and C viruses, in four high risk groups in Eritrea
Ghebrekidan H, Cox S, Wahren B, Grandien M
CLINICAL AND DIAGNOSTIC VIROLOGY 1998;9(1):29-35

Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81
Zhu J, Deng Gm, Levi M, Wahren B, Diab A, Van Der Meide Ph, et al
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 1998;57(3):291-301

Rapid analysis of epitope-paratope interactions between HIV-1 and a 17-amino-acid neutralizing microantibody by electrospray ionization mass spectrometry
Millar Al, Jackson Nac, Dalton H, Jennings Kr, Levi M, Wahren B, et al
EUROPEAN JOURNAL OF BIOCHEMISTRY 1998;258(1):164-9

Sequence variation within three important cytomegalovirus gene regions in isolates from four different patient populations
Wirgart Bz, Brytting M, Linde A, Wahren B, Grillner L
JOURNAL OF CLINICAL MICROBIOLOGY 1998;36(12):3662-9

Solid phase ELISA for determination of the virus dose dependant sensitivity of human cytomegalovirus to antiviral drugs in vitro
Stahle El, Schloss L, Sundqvist Va, Brytting M, Hokeberg I, Cox S, et al
ANTIVIRAL RESEARCH 1998;40(1-2):105-12

Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits
Isaguliants Mg, Kadoshnikov Yp, Kalinina Ti, Smirnov Vd, Wahren B
BIOCHEMISTRY-MOSCOW 1998;63(5):551-8

Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis
Zhang Gx, Shi Fd, Zhu J, Xiao Bg, Levi M, Wahren B, et al
JOURNAL OF NEUROIMMUNOLOGY 1998;85(1):96-101

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment
Bratt G, Karlsson A, Leandersson Ac, Albert J, Wahren B, Sandstrom E
AIDS 1998;12(16):2193-202

Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis
Zou Lp, Zhu J, Deng Gm, Levi M, Wahren B, Diab A, et al
JOURNAL OF NEUROIMMUNOLOGY 1998;85(2):137-45

DNA increases the potency of vaccination against infectious diseases
Wahren B, Brytting M
CURRENT OPINION IN CHEMICAL BIOLOGY 1997;1(2):183-9

HIV-1 epitopes exposed by hybrid hepatitis B core particles affect proliferation of peripheral blood mononuclear cells from HIV-1 positive donors (vol 52, pg 37, 1996)
Isaguliants Mg, Nordlund S, Sallberg M, Smirnov Vd, Ruden U, Wahren B
IMMUNOLOGY LETTERS 1997;55(1):61-61

Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine
Sasaki S, Fukushima J, Arai H, Kusakabe Ki, Hamajima K, Ishii N, et al
EUROPEAN JOURNAL OF IMMUNOLOGY 1997;27(12):3121-9

Induction of HIV-1 specific mucosal immune responses by DNA vaccination
Asakura Y, Hinkula J, Leandersson Ac, Fukushima J, Okuda K, Wahren B
SCANDINAVIAN JOURNAL OF IMMUNOLOGY 1997;46(4):326-30

Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic fab intrabodies against the matrix protein, p17
Levin R, Mhashilkar Am, Dorfman T, Bukovsky A, Zani G, Bagley J, et al
MOLECULAR MEDICINE 1997;3(2):96-110

Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, et al
JOURNAL OF IMMUNOLOGY 1997;159(7):3638-47

Linear epitope mapping of humoral responses induced by vaccination with recombinant HIV-1 envelope protein gp160
Loomisprice Ld, Levi M, Burnett Pr, Vanhamont Je, Shafer Ra, Wahren B, et al
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY 1997;19(1):58-65

Nucleic acid vaccination with HIV regulatory genes: A combination of HIV 1 genes in separate plasmids induces strong immune responses
Hinkula J, Lundholm P, Wahren B
VACCINE 1997;15(8):874-8

Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes
Hinkula J, Svanholm C, Schwartz S, Lundholm P, Brytting M, Engstrom G, et al
JOURNAL OF VIROLOGY 1997;71(7):5528-39

Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro
Krivorutchenko Yl, Andronovskaja Ib, Hinkula J, Krivoshein Ys, Ljungdahlstahle E, Pertel Ss, et al
VACCINE 1997;15(12-13):1479-86

The influence of MT-2 tropism on the prognostic implications of the Delta 32 deletion in the CCR-5 gene
Bratt G, Sandstrom E, Albert J, Samson M, Wahren B
AIDS 1997;11(12):1415-9

Analyses of functional antibody responses in HIV-1-infected individuals after vaccination with rgp160
Broliden K, Hinkula J, Bratt G, Persson C, Otero A, Ekstrom A, et al
CLINICAL AND DIAGNOSTIC VIROLOGY 1996;6(2-3):115-26

A prospective study of antibodies against parvovirus B19 in pregnancy
Skjoldebrandsparre L, Fridell E, Nyman M, Wahren B
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 1996;75(4):336-9

[Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. II. Combined analysis of immunogenicity of composite peptides in rabbits]
Isaruliants Mg, Ruden U, Wahren B
Biokhimiia (Moscow, Russia) 1996;61(7):1230-40

Detection of respiratory viruses in nasopharyngeal secretions with immunofluorescence technique for multiplex screening - An evaluation of the Chemicon assay
Shen Kl, Zhaori G, Zweygbergwirgart B, Ying M, Grandien M, Wahren B, et al
CLINICAL AND DIAGNOSTIC VIROLOGY 1996;6(2-3):147-54

[Expression of HIV-1 epitopes included in particles formed by human hepatitis B virus nucleocapsid protein]
Isaguliants Mg, Kadoshnikov Iup, Kalinina Ti, Khuliakov Iue, Semiletov Iua, Smirnov Vd, et al
Biokhimiia (Moscow, Russia) 1996;61(3):532-45

Expression of HIV-1 epitopes inserted into the nucleocapsid protein of human hepatitis B virus
Isaguliants Mg, Kadoshnikov Yp, Kalinina Ti, Khudyakov Ye, Semiletov Ya, Smirnov Vd, et al
BIOCHEMISTRY-MOSCOW 1996;61(3):393-403

Gene vaccines
Wahren B
IMMUNOTECHNOLOGY 1996;2(2):77-83

HIV-1 epitopes exposed by hybrid hepatitis B core particles affect proliferation of peripheral blood mononuclear cells from HIV-1 positive donors
Isaguliants Mg, Nordlund S, Sallberg M, Smirnov Vd, Ruden U, Wahren B
IMMUNOLOGY LETTERS 1996;52(1):37-44

Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity
Broliden K, Vongegerfelt A, Persson C, Horal P, Svennerholm B, Wahren B, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 1996;12(18):1699-702

Immune responses to the HIV rev regulatory gene
Wahren B, Brytting Mm, Engström G, Hinkula J, Levi M, Ståhle El, et al
Antibiotics and chemotherapy 1996;48():105-12

Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals
Calarota S, Jansson M, Levi M, Broliden K, Libonatti O, Wigzell H, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 1996;12(8):705-13

Inhibition of SIV and HIV-2 replication in cynomolgus monkeys by (-)9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G)
Bottiger D, Johansson Ng, Lind P, Lindborg B, Noreen R, Putkonen P, et al
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY 1996;7(1):21-26

In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160
Pincus Sh, Wehrly K, Cole R, Fang H, Lewis Gk, Mcclure J, et al
AIDS RESEARCH AND HUMAN RETROVIRUSES 1996;12(11):1041-51

Linear fusion of HIV-1 B-epitopes and heterologous T-cell epitopes .1. Preservation of the antigenic properties of the HIV-1 B-cell epitopes
Isaguliants Mg, Koshida R, Ruden U, Wahren B
BIOCHEMISTRY-MOSCOW 1996;61(7):872-877

Linear fusion of HIV-1 B-epitopes and heterologous T-Cell epitopes .2. Multiparametric assay of immunogenicity of composite peptides in rabbits
Isaguliants Mg, Ruden U, Wahren B
BIOCHEMISTRY-MOSCOW 1996;61(7):878-885

Multicenter study of safety and immunogenicity of HIV-1 rgp160 candidate vaccine in seropositive HIV-1 volunteers.
Goebel Fd, Mannhalter Jw, Eibl Mm, Belshe Rb, Grob P, Erfle V, et al
AIDS 1996;:OP64-OP64

Peptide sequences of glycoprotein G-2 discriminate between herpes simplex virus type 2 (HSV-2) and HSV-1 antibodies
Levi M, Ruden U, Wahren B
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 1996;3(3):265-9

Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: Analysis of immunological mimicry
Lundin K, Samuelsson A, Jansson M, Hinkula J, Wahren B, Persson Maa
IMMUNOLOGY 1996;89(4):579-86

Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients
Cinque P, Vago L, Dahl H, Brytting M, Terreni Mr, Fornara C, et al
AIDS 1996;10(9):951-8

Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1
Armstrong Sj, Mcinerney Tl, Mclain L, Wahren B, Hinkula J, Levi M, et al
JOURNAL OF GENERAL VIROLOGY 1996;:2931-41

Viral etiology of acute childhood encephalitis in Beijing diagnosed by analysis of single samples
Xu Yh, Zhaori G, Vene S, Shen Kl, Zhou Yt, Magnius Lo, et al
PEDIATRIC INFECTIOUS DISEASE JOURNAL 1996;15(11):1018-24

CERVICAL-CANCER AND HERPES-SIMPLEX VIRUS TYPE-2 - CASE-CONTROL STUDIES IN SPAIN AND COLOMBIA, WITH SPECIAL REFERENCE TO IMMUNOGLOBULIN-G SUBCLASSES
Munoz N, Kato I, Bosch Fx, Desanjose S, Sundquist Va, Izarzugaza I, et al
INTERNATIONAL JOURNAL OF CANCER 1995;60(4):438-42

CONTINUOUS DETECTION OF CMV DNA IN PLASMA OF PATIENTS WITH ADVANCED HIV-INFECTION IMPLIES THE POOREST PROGNOSIS
Wang Fh, Brytting M, Bratt G, Ljungman P, Wahren B
CLINICAL AND DIAGNOSTIC VIROLOGY 1995;3(4):371-5

CYTOTOXICITY OF 3'-AZIDO-3'-DEOXYTHYMIDINE CORRELATES WITH 3'-AZIDOTHYMIDINE-5'-MONOPHOSPHATE (AZTMP) LEVELS, WHEREAS ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ACTIVITY CORRELATES WITH 3'-AZIDOTHYMIDINE-5'-TRIPHOSPHATE (AZTTP) LEVELS IN CULTURED CEM T-LYMPHOBLASTOID CELLS
Tornevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S
BIOCHEMICAL PHARMACOLOGY 1995;49(6):829-37

ENZYME-LINKED IMMUNOSORBENT ASSAY-BASED INHIBITION TEST FOR NEUTRALIZING ANTIBODIES TO POLIOVIRUSES AS AN ALTERNATIVE TO THE NEUTRALIZATION TEST IN TISSUE-CULTURE
Edevag G, Wahren B, Osterhaus Adme, Sundqvist Va, Granstrom M
JOURNAL OF CLINICAL MICROBIOLOGY 1995;33(11):2927-30

INCREASED MESSENGER-RNA EXPRESSION OF IL-6, IL-10, TNF-ALPHA, AND PERFORIN IN BLOOD MONONUCLEAR-CELLS IN HUMAN HIV-INFECTION
Navikas V, Link J, Persson C, Olsson T, Hojeberg B, Ljungdahl A, et al
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 1995;9(5):484-9

MIMICKING THE HUMORAL IMMUNE-RESPONSE IN-VITRO RESULTS IN ANTIGEN-SPECIFIC ISOTYPE SWITCHING SUPPORTED BY SPECIFIC AUTOLOGOUS T-HELPER CELLS - GENERATION OF HUMAN HIV-1-NEUTRALIZING IGG MONOCLONAL-ANTIBODIES FROM NAIVE DONORS
Chin Lt, Malmborg Ac, Kristensson K, Hinkula J, Wahren B, Borrebaeck Cak
EUROPEAN JOURNAL OF IMMUNOLOGY 1995;25(3):657-63

MOLECULAR CHARACTERIZATION OF A HUMAN ANTI-HIV-1 MONOCLONAL-ANTIBODY REVEALED A CD26-RELATED MOTIF IN CDR2
Chin Lt, Duenas M, Levi M, Hinkula J, Wahren B, Borrebaeck Cak
IMMUNOLOGY LETTERS 1995;44(1):25-30

MONOCLONAL-ANTIBODIES TO P24-CORE PROTEIN OF HIV-1 MEDIATE ADCC AND INHIBIT VIRUS SPREAD IN-VITRO
Grunow R, Franke L, Hinkula J, Wahren B, Fenyo Em, Jondal M, et al
CLINICAL AND DIAGNOSTIC VIROLOGY 1995;3(3):221-31

NUCLEIC-ACID VACCINATION WITH HIV REGULATORY AND STRUCTURAL GENES
Wahren B, Hinkula J, Ljungdahlstahle E, Schwartz S, Wigzell S
AIDS RESEARCH AND HUMAN RETROVIRUSES 1995;:S146-S146

Nucleic acid vaccination with HIV regulatory genes
Wahren B, Hinkula J, Stahle El, Borrebaeck Cak, Schwartz S, Wigzell H
DNA VACCINES 1995;:278-81

REPORT OF A CONSENSUS WORKSHOP, SIENA, ITALY, JUNE 3-6, 1993 - STRATEGIES FOR PREVENTION OF PERINATAL TRANSMISSION OF HIV-INFECTION
Ammann A, Chiecobianchi L, Bryson Y, Coll O, Dabis F, Demaria A, et al
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 1995;8(2):161-175

[Vaccination with the naked DNA. Revolutionary news against infectious diseases]
Wahren B
Lakartidningen 1995;92(26-27):2653-4

Show all publications